Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: J Allergy Clin Immunol Pract. 2019 Aug 29;8(1):91–101. doi: 10.1016/j.jaip.2019.06.044

FIGURE 4.

FIGURE 4.

AD-1526: dupilumab in adolescents with moderate-to-severe AD in AD-1526.62 Dupilumab was significantly more effective than control for both primary endpoints (percentage achieving an IGA score of 0 or 1 and percentage achieving EASI-75). AD, Atopic dermatitis; EASI, Eczema Area and Severity Index; IGA, Investigator Global Assessment.